1. NCCN Guidelines® insights: non-small cell lung cancer, version 2.2023;Ettinger;J Natl Compr Canc Netw,2023
2. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018
3. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer;Peters;N Engl J Med,2017
4. US Food & Drug FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations Accessed: December 10, 2023
5. NIH National Cancer Institute. FDA approves alectinib for initial treatment of ALK-positive lung cancer. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2017/alectinib-fda-untreated-lung-cancer Accessed: December 10, 2023